Replies to post #18644 on BioCurex, Inc.(fka BOCX)

[Gold Seeker]

Half, your assumption that I agree with you is incorrect. The HaaH marker studies had 99% sensitivity and 93% specificity for lung cancer. If you want to start comparing studies verses studies then, I think the HAAH marker may have better numbers than RECAF. Why isn't it selling? Also, if you restrict this comparison to studies and not include clinical trials, the DR70 marker does well also.

[Gold Seeker]

Half stated: "Did Abbott and or Inverness buy site unseen or did they perform testing of their own before they forked over millions?"

I was not aware that Abbott "forked over millions" for RECAF. If you check the filings, Abbott gave Moro $200,000 up front and one $50,000 minimum royalty payment. For some reason, the next minimum royalty payment was given away in the amendment signed last year. The Abbott contract contained a milestone for the completion of a feasibility study but RECAF was apparently not ever determined to be a feasible product. The feasibility milestone was never paid.

As for Inverness, they paid two payments of $500,000 each but there are no milestone payments as were in the Abbott contract so Inverness has not "forked over millions" either.